Koers DelMar Pharmaceuticals Inc Nasdaq
Aandelen
US2470782077
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 6,82 mln. 6,39 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -22 mln. -20,62 mln. | Nettowinst (verlies) 2023 | -14 mln. -13,12 mln. | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 11,78 mln. 11,04 mln. | Nettoliquiditeiten 2023 | 2,61 mln. 2,45 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-0,54
x | K/w-verhouding 2023 |
-0,43
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 99,81% |
Recentste transcriptie over DelMar Pharmaceuticals Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Hoffman
CEO | Chief Executive Officer | 58 | 11-04-18 |
Greg Johnson
COO | Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Hoffman
CEO | Chief Executive Officer | 58 | 11-04-18 |
Tamara Favorito
BRD | Director/Board Member | 65 | 29-04-21 |
Laura Douglass
BRD | Director/Board Member | 59 | 26-06-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,46% | 102 mld. | |
+1,41% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-15,84% | 21,4 mld. | |
-9,98% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-14,65% | 16,09 mld. | |
+4,39% | 13,83 mld. | |
+31,35% | 11,97 mld. |